ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Proposal

Rigrodsky & Long, P.A.:
  • Do you own shares of Allergan, Inc. (NYSE: AGN )?
  • Did you purchase any of your shares prior to April 22, 2014?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Allergan, Inc. (“Allergan” or the “Company”) (NYSE: AGN) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s receipt of a proposal to be acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE: VRX), in a transaction valued at approximately $45 billion.

Click here to learn more:

Under the terms of the proposal, public shareholders of Allergan would receive $48.30 in cash and 0.83 shares of Valeant common stock for each share of Allergan they own. Based on Valeant’s closing stock price on April 21, 2014, Allergan shareholders would have received consideration valued at approximately $152.88 per share.

The investigation concerns the Allergan’s board of directors’ process for consideration of the proposed transaction, whether the Company is acting in its shareholders’ best interests and whether the proposed consideration to be paid to Allergan’s shareholders would be fair and adequate.

If you own the common stock of Allergan and purchased your shares before April 22, 2014, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, Delaware 19803; by telephone at (888) 969-4242; or by e-mail to, or at:

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)